189 related articles for article (PubMed ID: 29279479)
1. Fatal Disseminated Tuberculosis during Treatment with Ruxolitinib Plus Prednisolone in a Patient with Primary Myelofibrosis: A Case Report and Review of the Literature.
Tsukamoto Y; Kiyasu J; Tsuda M; Ikeda M; Shiratsuchi M; Ogawa Y; Yufu Y
Intern Med; 2018 May; 57(9):1297-1300. PubMed ID: 29279479
[TBL] [Abstract][Full Text] [Related]
2. Fatal Disseminated Tuberculosis and Concurrent Disseminated Cryptococcosis in a Ruxolitinib-treated Patient with Primary Myelofibrosis: A Case Report and Literature Review.
Ogai A; Yagi K; Ito F; Domoto H; Shiomi T; Chin K
Intern Med; 2022 Apr; 61(8):1271-1278. PubMed ID: 34565769
[TBL] [Abstract][Full Text] [Related]
3. [Fatal tuberculosis during treatment with ruxolitinib].
Keizer S; Gerritsen R; Jauw Y; Janssen J; Koopman B; Bresser P
Ned Tijdschr Geneeskd; 2015; 159():A8650. PubMed ID: 25990328
[TBL] [Abstract][Full Text] [Related]
4. Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis.
Pugliese N; Giordano C; Nappi D; Luciano L; Cerchione C; Annunziata M; Casale B; Crisà E; Villa MR; Pezzullo L; Iovine M; Picardi M; Grimaldi F; Pane F; Martinelli V
Cancer Med; 2019 Jun; 8(6):2802-2809. PubMed ID: 30997748
[TBL] [Abstract][Full Text] [Related]
5. Combination Therapy with Ruxolitinib and Hydroxyurea for the Treatment of Myeloid-Predominant Leukocytosis in a Patient with Myelofibrosis.
Caocci G; Ghiani S; Mocci C; La Nasa G
Acta Haematol; 2018; 139(3):164-165. PubMed ID: 29597187
[No Abstract] [Full Text] [Related]
6. Ruxolitinib Treatment in a Patient with Primary Myelofibrosis Resistant to Conventional Therapies and Splenectomy: A Case Report.
Aylı M; Özcan M; Cengiz Seval G
Turk J Haematol; 2015 Jun; 32(2):180-3. PubMed ID: 26316489
[TBL] [Abstract][Full Text] [Related]
7. Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea.
Pacilli A; Rotunno G; Mannarelli C; Fanelli T; Pancrazzi A; Contini E; Mannelli F; Gesullo F; Bartalucci N; Fattori GC; Paoli C; Vannucchi AM; Guglielmelli P
Blood Cancer J; 2018 Nov; 8(12):122. PubMed ID: 30467377
[TBL] [Abstract][Full Text] [Related]
8. Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN.
Breccia M; Andriani A; Montanaro M; Abruzzese E; Buccisano F; Cedrone M; Centra A; Villivà N; Celesti F; Trawinska MM; Massaro F; Di Veroli A; Anaclerico B; Colafigli G; Molica M; Spadea A; Petriccione L; Cimino G; Latagliata R
Ann Hematol; 2017 Mar; 96(3):387-391. PubMed ID: 27889820
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis.
Breccia M; Luciano L; Pugliese N; Rossi E; Tiribelli M; Scalzulli E; Bonifacio M; Martino B; Latagliata R; Benevolo G; Caocci G; Binotto G; Martinelli V; Cavo M; Pane F; De Stefano V; Foà R; Palandri F
Ann Hematol; 2019 Aug; 98(8):1933-1936. PubMed ID: 31201513
[TBL] [Abstract][Full Text] [Related]
10. Fatal ruxolitinib-related JC virus meningitis.
Ballesta B; González H; Martín V; Ballesta JJ
J Neurovirol; 2017 Oct; 23(5):783-785. PubMed ID: 28791626
[TBL] [Abstract][Full Text] [Related]
11. Tuberculosis reactivation related with ruxolitinib in a patient with primary myelofibrosis.
Pepeler MS; Özkurt ZN; Güzel ÖT; Akyürek N
J Infect Dev Ctries; 2018 Oct; 12(10):926-928. PubMed ID: 32004164
[TBL] [Abstract][Full Text] [Related]
12. Osteolytic Lesions in Primary Myelofibrosis and Effect of Ruxolitinib Therapy: Report of a Case and Literature Review.
Bucelli C; Cattaneo D; Valli VB; Levati GV; Lonati S; Gianelli U; Iurlo A
Chemotherapy; 2018; 63(6):340-344. PubMed ID: 30965327
[TBL] [Abstract][Full Text] [Related]
13. Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation.
Beauverd Y; Samii K
Int J Hematol; 2014 Nov; 100(5):498-501. PubMed ID: 25034748
[TBL] [Abstract][Full Text] [Related]
14. Use of rifampin for treatment of disseminated tuberculosis in a patient with primary myelofibrosis on ruxolitinib.
Branco B; Metsu D; Dutertre M; Marchou B; Delobel P; Recher C; Martin-Blondel G
Ann Hematol; 2016 Jun; 95(7):1207-9. PubMed ID: 27113251
[No Abstract] [Full Text] [Related]
15. Efficacy and safety of ruxolitinib in patients with myelofibrosis: a retrospective and multicenter experience in Turkey.
Soyer N; Ali R; Turgut M; Haznedaroğlu İC; Yılmaz F; Aydoğdu İ; Pir A; Karakuş V; Özgür G; Kiş C; Ceran F; İlhan G; Özkan M; Aslaner M; İnce İ; Yavaşoğlu İ; Gediz F; Sönmez M; Güvenç B; Özet G; Kaya E; Vural F; Şahin F; Töbü M; Durusoy R; Saydam G
Turk J Med Sci; 2021 Jun; 51(3):1033-1042. PubMed ID: 33315343
[TBL] [Abstract][Full Text] [Related]
16. Ruxolitinib - better prognostic impact in low-intermediate 1 risk score: evaluation of the 'rete ematologica pugliese' (REP) in primary and secondary myelofibrosis.
Mazza P; Specchia G; Di Renzo N; Cascavilla N; Tarantini G; Capalbo SF; Urbano T; Albano F; Giovannni R; Falcone AP; Santeramo MT; Spinosa G; Pisconti S
Leuk Lymphoma; 2017 Jan; 58(1):138-144. PubMed ID: 27263544
[TBL] [Abstract][Full Text] [Related]
17. Cryptococcal fungemia and Mycobacterium haemophilum cellulitis in a patient receiving ruxolitinib: a case report and literature review.
Sayabovorn N; Chongtrakool P; Chayakulkeeree M
BMC Infect Dis; 2021 Jan; 21(1):27. PubMed ID: 33413168
[TBL] [Abstract][Full Text] [Related]
18. Isolated Nodal TBC Reactivation in a Patient with Post-Thrombocythemia Myelofibrosis Treated with Ruxolitinib: Case Report and Review of the Literature.
Santoro M; Rotolo C; Accurso V; Morreale I; Mancuso S; Siragusa S
Chemotherapy; 2021; 66(3):87-91. PubMed ID: 33784668
[TBL] [Abstract][Full Text] [Related]
19. Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report.
Colomba C; Rubino R; Siracusa L; Lalicata F; Trizzino M; Titone L; Tolomeo M
BMC Res Notes; 2012 Oct; 5():552. PubMed ID: 23039051
[TBL] [Abstract][Full Text] [Related]
20. Secondary Pulmonary Alveolar Proteinosis Associated with Primary Myelofibrosis and Ruxolitinib Treatment: An Autopsy Case.
Sugiura H; Nishimori H; Nishii K; Toji T; Fujii K; Fujii N; Matsuoka KI; Nakata K; Kiura K; Maeda Y
Intern Med; 2020 Aug; 59(16):2023-2028. PubMed ID: 32448830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
